Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people requiring an organ or cellular transplant, and for people living with autoimmune and neurodegenerative disease. The firm’s compound in development is AT-1501, a humanized IgG1 anti-CD40L antibody with high affinity for CD40 ligand (CD40L, also called CD154), a well-validated biological target with broad therapeutic potential. The CD40L/CD40 pathway is recognized for its prominent role in immune regulation, making it a candidate for therapeutic intervention in transplant tolerance, autoimmune disease, and neuro-inflammation. The company is building upon a deep historical understanding of the CD40/CD40L pathway, as well as preclinical and Phase 1 data, to initiate up to four phase 2 clinical studies with AT-1501. Eledon Pharmaceuticals was founded on March 26, 2004 and is headquartered in Irvine, CA.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
12
Frequently Asked Questions
What is market cap of Eledon Pharmaceuticals Inc?
The market cap of Eledon Pharmaceuticals Inc is $34.39M
What is the 52 week high for Eledon Pharmaceuticals Inc?
The 52 week high for Eledon Pharmaceuticals Inc is $4.15.
What is the 52 week low for Eledon Pharmaceuticals Inc?
The 52 week low for Eledon Pharmaceuticals Inc is $1.90.
What is Eledon Pharmaceuticals Inc stock price today?
Eledon Pharmaceuticals Inc' stock price today is $2.30.
What is the pe ratio of Eledon Pharmaceuticals Inc?
The PE ratio of Eledon Pharmaceuticals Inc is -0.93.
What is the price to book ratio of Eledon Pharmaceuticals Inc?
The price to book ratio of Eledon Pharmaceuticals Inc is 0.2438.
What is Eledon Pharmaceuticals Inc's EBITDA?
Eledon Pharmaceuticals Inc's EBITDA is -38.784.
What is the 50-day moving average of Eledon Pharmaceuticals Inc?
The 50-day moving average of Eledon Pharmaceuticals Inc is 2.7165.
How many employess does Eledon Pharmaceuticals Inc has?